Tema ETFs
TRAX icon

Tema ETFs’s First Tracks Biotherapeutics TRAX Stock Holding History

Tema ETFs’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-30,907
Closed -$622K – 621
2026
Q2 		$622K Buy
+30,907
New +$578K 0.02% 373

Other funds holding TRAX

Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Adirondack Trust Company
Adirondack Trust Company Saratoga Springs, New York $320M AUM 23.25% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Tema ETFs's TRAX Position: Q3 2026 in Review

Tema ETFs sold out of First Tracks Biotherapeutics (TRAX) in Q3 2026, closing a stake of 30,907 shares — an estimated $622K sold.

Tema ETFs first reported a position in TRAX in Q2 2026 and held it in 1 quarter. The position peaked at $622K in Q2 2026. 11 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

  • Tema ETFs reported no remaining First Tracks Biotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Tema ETFs sold 30,907 First Tracks Biotherapeutics shares in Q3 2026, an estimated $622K.
  • Tema ETFs first reported a position in First Tracks Biotherapeutics in Q2 2026 and held it in 1 quarter.
  • Tema ETFs's First Tracks Biotherapeutics position peaked at $622K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on Tema ETFs's 13F filing for Q3 2026, filed 16 Oct 2026.